ArticleCardiovascular diabetology2017
Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels.
Article in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- A Randomized-Controlled Trial Pilot Study Examining the Effect of Pelvic Floor Muscle Training on the Irisin Concentration in Overweight or Obese Elderly Women with Stress Urinary Incontinence.BioMed research international · 2019Trial
- Review
- Beyond glycemia: adropin, asprosin, and irisin as potential biomarkers for cardiovascular risk in diabetes and prediabetes.Scientific reports · 2026Article
- Association of Circulating Irisin with Insulin Resistance and Metabolic Risk Markers in Prediabetic and Newly Diagnosed Type 2 Diabetes Patients.International journal of molecular sciences · 2026Article
- Circulating organokines in coronary artery disease and metabolic syndrome: FABP4, adiponectin, irisin, FSTL1.Biomolecules & biomedicine · 2025Article
- Prenatal irisin is inversely related to the term placental telomere length.BMC research notes · 2025Article
- The protective effect of irisin against hemorrhagic injury is mediated by PI3K and p38 pathways in hemorrhage/resuscitation.The Journal of pharmacology and experimental therapeutics · 2025Article
- Relationship between serum irisin levels and renal function in patients with type 2 diabetes mellitus.Caspian journal of internal medicine · 2025Article
- A case-control study to evaluate irisin levels in patients with type 1 diabetes mellitus.Irish journal of medical science · 2024Article
- Irisin and Triglyceride Glucose Index as Markers of Dyslipidemia in Young Adults.Indian journal of clinical biochemistry : IJCB · 2024Article
- Association between Serum Irisin and Leptin Levels and Risk of Depressive Symptoms in the Diabetic Elderly Population.Journal of clinical medicine · 2023Article
- Oxidative Stress, Reductive Stress and Antioxidants in Vascular Pathogenesis and Aging.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- The Potential Relationship Between Serum Irisin Concentration With Inflammatory Cytokines, Oxidative Stress Biomarkers, Glycemic Indices and Lipid Profiles in Obese Patients With Type 2 Diabetes Mellitus: A Pilot Study.Journal of the ASEAN Federation of Endocrine Societies · 2023Article
- Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.International journal of endocrinology · 2023Article
- Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature.Journal of clinical medicine · 2022Review
- Irisin promotes fracture healing by improving osteogenesis and angiogenesis.Journal of orthopaedic translation · 2022Article
- Irisin reduces inflammatory signaling pathways in inflammation-mediated metabolic syndrome.Molecular and cellular endocrinology · 2022Review
- Clinical Importance of FNDC-5 and Selectin-E mRNA Expression Among Type 2 Diabetics with and without Obesity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- The Association of Serum Irisin with Bone Mineral Density and Turnover Markers in New-Onset Type 2 Diabetic Patients.International journal of endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrisin is a hormone released mainly from skeletal muscle after exercise which increases adipose tissue energy expenditure. Adipocytes can also release irisin after exercise, acting as a local adipokine to induce white adipose tissue to take on a brown adipose tissue-like phenotype, suggesting that irisin and its receptor may represent a novel molecular target for the treatment of obesity and obesity-related diabetes. Previous reports provide conflicting evidence regarding circulating irisin levels in patients with type 2 diabetes (T2DM).
methodsThis study investigated plasma irisin concentrations in 79 T2DM individuals, assessing potential associations with measures of segmental body composition, markers of endothelial dysfunction and peripheral blood mononuclear cell telomere length (TL).
resultsResting, overnight-fasted plasma irisin levels were significantly higher in this group of T2DM patients compared with levels we previously reported in healthy volunteers (p < 0.001). Moreover, plasma irisin displayed a positive correlation with body mass index (p = 0.04), body fat percentage (p = 0.03), HbA1c (p = 0.03) and soluble E-selectin (p < 0.001). A significant negative association was observed between plasma irisin and visceral adiposity (p = 0.006) in T2DM patients. Multiple regression analysis revealed that circulating soluble E-selectin levels could be predicted by plasma irisin (p = 0.004). Additionally, cultured human umbilical vein endothelial cells (HUVEC) exposed to 200 ng/ml irisin for 4 h showed a significant fourfold increase in E-selectin and 2.5-fold increase in ICAM-1 gene expression (p = 0.001 and p = 0.015 respectively), and there was a 1.8-fold increase in soluble E-selectin in conditioned media (p < 0.05).
conclusionThese data suggest that elevated plasma irisin in T2DM is associated with indices of adiposity, and that irisin may be involved in pro-atherogenic endothelial disturbances that accompany obesity and T2DM. Accordingly, irisin may constitute a potentially novel therapeutic opportunity in the field of obesity and cardiovascular diabetology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.